ArticleMolecular medicine reports2017
miR‑4262 inhibits colon cancer cell proliferation via targeting of GALNT4.
Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- TRIM23 promotes 5-Fluorouracil resistance in colorectal cancer by upregulating GALNT4 expression.Apoptosis : an international journal on programmed cell death · 2025Article
- miR-23a-3p promotes the development of colon cancer by inhibiting the expression of NDRG4.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Hsa_circ_0001550 facilitates colorectal cancer progression through mediating microRNA-4262/nuclear casein kinase and cyclin-dependent kinase substrate 1 cascade.Journal of clinical laboratory analysis · 2022Article
- The Role of Glycosyltransferases in Colorectal Cancer.International journal of molecular sciences · 2021Review
- Epigenetic Regulation of Glycosylation in Cancer and Other Diseases.International journal of molecular sciences · 2021Review
- CRNDE Contributes Cervical Cancer Progression by Regulating miR-4262/ZEB1 Axis.OncoTargets and therapy · 2021Article
- Epigenetic Regulation of Glycosylation.Advances in experimental medicine and biology · 2021Article
- Article
- Prognostic Significance of Alternative Splicing Genes in Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma.International journal of general medicine · 2021Article
- Sweet Control: MicroRNA Regulation of the Glycome.Biochemistry · 2020Review
- miR-365b regulates the development of non-small cell lung cancer via GALNT4.Experimental and therapeutic medicine · 2020Article
- MicroRNA-374c-5p inhibits the development of breast cancer through TATA-box binding protein associated factor 7-mediated transcriptional regulation of DEP domain containing 1.Journal of cellular biochemistry · 2019Article
- NFKB1-miR-612-FAIM2 pathway regulates tumorigenesis in neurofibromatosis type 1.In vitro cellular & developmental biology. Animal · 2019Article
- miR-30c Impedes Glioblastoma Cell Proliferation and Migration by Targeting SOX9.Oncology research · 2019Article
- miR‑3666 suppresses cellular proliferation and invasion in colorectal cancer by targeting SATB2.Molecular medicine reports · 2018Article
- miR19b-3p promotes the growth and metastasis of colorectal cancer via directly targeting ITGB8.American journal of cancer research · 2017Article
- ppGalNAc-T4-catalyzed O-Glycosylation of TGF-β type Ⅱ receptor regulates breast cancer cells metastasis potential.The Journal of biological chemistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRs) have been demonstrated to be important in the establishment and progression of colon cancer. However the underlying molecular mechanisms remain to be fully elucidated. Polypeptide N‑acetylgalactosaminyltransferase4 (GALNT4) participates in numerous cellular processes, including tumorigenesis. The present study used reverse transcription‑quantitative polymerase chain reaction and western blotting to investigate the expression levels of miR‑4262 and GALNT4 in tissues and cells. In addition, MTS and colony formation assays, and cell cycle analysis were performed to evaluate the effect of miR‑4262 on cell proliferation and the cell cycle. The findings demonstrated that miR‑4262 was a direct target of GALNT4 mRNA. Overexpression of miR‑4262 was demonstrated to decrease GALNT4 mRNA and protein expression levels, and thereby suppressed cell viability, growth and cell‑cycle progression in SW480 and SW620 colon cancer cells. In addition, knockdown of miR‑4262 significantly increased the cell viability, growth, and cell‑cycle progression of SW480 and SW620 cells. The expression level of miR‑4262 was observed to be downregulated as the expression of GALNT4 was upregulated in colon cancer tissues and cell lines. In conclusion, the results demonstrated that miR‑4262 may be involved in the development of colon cancer via targeting of GALNT4. The miR‑4262/GALNT4 axis may be a novel target for diagnosing and understanding the underlying molecular mechanism of colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.